Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR plus NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy

被引：0

作者：

Saalfeld, F. C. ^{[1
]}

Moeller, J. ^{[1
]}

Michels, S. ^{[2
]}

Grohe, C. ^{[3
]}

Wiesweg, M. ^{[4
]}

Schubart, C. ^{[5
]}

Alt, J. ^{[6
]}

Griesinger, F. ^{[7
]}

Kauffmann-Guerrero, D. ^{[8
]}

Kulhavy, J. ^{[9
]}

Overbeck, T. R. ^{[10
]}

Pelusi, N. ^{[11
]}

Rohde, G. ^{[12
]}

Wesseler, C. ^{[13
]}

Vathiotis, I. ^{[14
]}

Veluswamy, R. ^{[15
]}

Illini, O. M. ^{[16
]}

Rothschild, S. I. ^{[17
]}

Christopoulos, P. ^{[18
]}

Wermke, M. ^{[1
]}

机构：

[1] Tech Univ Dresden, Univ Hosp Carl Gustav Carus Dresden, Clin Internal Med 1, Dresden, Germany

[2] Univ Cologne, Univ Hosp, Dept Internal Med 1, Cologne, Germany

[3] ELK Berlin, Dept Resp Dis, Berlin, Germany

[4] Univ Duisburg Essen, Dept Med Oncol, West German Canc Ctr, Essen, Germany

[5] Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Hosp Erlangen, Inst Pathol, Erlangen, Germany

[6] Johannes Gutenberg Univ Mainz, Dept Hematol & Oncol, Univ Med Ctr, Mainz, Germany

[7] Univ Med Oldenburg, Pius Univ Hosp, Dept Hematol & Oncol, Oldenburg, Germany

[8] Univ Munich LMU, Univ Hosp, Div Resp Med & Thorac Oncol, Dept Med, Munich, Germany

[9] Univ Hosp Wuerzburg, Comprehens Canc Ctr Mainfranken, Early Clin Trial Unit ECTU, Wurzburg, Germany

[10] Univ Gottingen, Univ Med Ctr Gottingen, Dept Hematol & Med Oncol, Gottingen, Germany

[11] Univ Hosp Bonn UKB, Inst Pathol, Bonn, Germany

[12] Johannes Wolfgang Goethe Univ, Med Clin 1, Dept Resp Med, Univ Klinikum Frankfurt, Frankfurt, Germany

[13] Klinikum Harburg, Asklepios Tumorzentrum Hamburg, Dept Pneumol, Hamburg, Germany

[14] Sotiria Thorac Dis Hosp Athens, Dept Med 3, Athens, Greece

[15] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY USA

[16] Klin Floridsdorf, Vienna Healthcare Grp, Karl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Vienna, Austria

[17] Cantonal Hosp Baden, Ctr Oncol Hematol, Baden, Switzerland

[18] Univ Heidelberg Hosp, Thoraxklin, Heidelberg, Germany

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2369

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1336P

引用

页数：1

共 50 条

[31] The role of EGFR tyrosine kinase inhibitors in the treatment of non-small cell lung cancer
Kowalczyk, Anna
Szutowicz-Zielinska, Ewa
Dziadziuszko, Rafal
Jassem, Jacek
ONCOLOGY IN CLINICAL PRACTICE, 2005, 1 (04): : 217 - 224
[32] Sequential treatment of tyrosine kinase inhibitors and chemotherapy for EGFR-mutated non-small cell lung cancer: a meta-analysis of Phase III trials
Zhang, Yiliang
Sun, Yihua
Wang, Lei
Ye, Ting
Pan, Yunjian
Hu, Haichuan
Yu, Yongfu
Zhao, Naiqing
Song, Yanyan
Garfield, David
Chen, Haiquan
ONCOTARGETS AND THERAPY, 2013, 6 : 1771 - 1777
[33] Sequential Treatment of Tyrosine Kinase Inhibitors and Chemotherapy for EGFR-Mutated Non-small Cell Lung Cancer: A Meta-analysis of Phase III Trials
Zhang, Yiliang
Sun, Yihua
Wang, Lei
Ye, Ting
Pan, Yunjian
Hu, Haichuan
Yu, Yongfu
Garfield, David
Chen, Haiquan
CHEST, 2014, 145 (03)
[34] Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials
Petrelli, Fausto
Borgonovo, Karen
Cabiddu, Mary
Barni, Sandro
CLINICAL LUNG CANCER, 2012, 13 (02) : 107 - 114
[35] Developing of EGFR resistant mutations to Tyrosine Kinase Inhibitors (TKI) in Non-Small Cell Lung Cancer (NSCLC)
Raez, L. E.
Baca, Y.
Nagasaka, M.
Nieva, J.
Mandani, H.
Wanderwalde, A.
Borghaei, H.
Naban, C.
Langer, C.
Socinsky, M. A.
Lopes, G.
Khan, H.
Wozniak, A.
Carracedo, C.
Liu, S.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S597 - S597
[36] Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy
Zhong, Hua
Zhang, Xueyan
Tian, Panwen
Chu, Tianqing
Guo, Qisen
Yu, Xinmin
Yu, Zhuang
Li, Yalun
Chen, Lijuan
Liu, Jie
Zhang, Yan
Guan, Yan
Shi, Xun
Wang, Jing
Zhao, Yanqiu
Han, Baohui
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (08)
[37] Plasma metabolite biomarkers for EGFR-mutated non-small cell lung cancer (NSCLC)
Thamlikitkul, Lucksamon
Manocheewa, Siriphan
Limjiasahapong, Suphitcha
Wanichthanarak, Kwanjeera
Panya, Atikorn
Poungvarin, Naravat
Pomyen, Yotsawat
Khoomrung, Sakda
CANCER RESEARCH, 2024, 84 (06)
[38] Integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutation
Maevskaya, J.
Laktionov, K.
Yudin, D.
Vladimirova, L.
ANNALS OF ONCOLOGY, 2020, 31 : S1402 - S1402
[39] The efficacy and safety of immune checkpoint inhibitors for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy: A systematic review and network meta-analysis
Wang, Zhen
Zhou, Fang
Xu, Shan
Wang, Kang
Ding, Huan
CANCER MEDICINE, 2023, 12 (18): : 18516 - 18530
[40] Longitudinal circulating-tumor DNA profiling of EGFR-mutated non-small cell lung cancer patients treated with EGFR-tyrosine kinase inhibitors
Ortiz-Cuaran, Sandra
Swalduz, Aurelie
Leonce, Camille
Marteau, Solene
Martinez, Severine
Clapisson, Gilles
Avrillon, Virginie
Odier, Luc
Falchero, Lionel
Fournel, Pierre
Green, Emma
Morris, Clive
Perol, Maurice
Saintingy, Pierre
CANCER RESEARCH, 2018, 78 (13)

← 1 2 3 4 5 →